NASDAQ:RNXT RenovoRx Q3 2025 Earnings Report $1.29 +0.20 (+18.35%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.26 -0.03 (-1.94%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast RenovoRx EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/ARenovoRx Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARenovoRx Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile RenovoRx Earnings HeadlinesRenovoRx expands Scientific Advisory Board with appointment of BaereOctober 9, 2025 | msn.comRenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhDOctober 9, 2025 | globenewswire.comElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. Don’t miss your chance. | Angel Publishing (Ad)RenovoRx announces first patient procedure completed in PanTheR studySeptember 25, 2025 | msn.comRenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical SitesSeptember 25, 2025 | finance.yahoo.comRenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical SitesSeptember 25, 2025 | globenewswire.comSee More RenovoRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email. Email Address About RenovoRxRenovoRx (NASDAQ:RNXT) is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers. RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets. Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.View RenovoRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings HDFC Bank (10/17/2025)Truist Financial (10/17/2025)American Express (10/17/2025)Nasdaq (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
